Crinetics Pharmaceuticals Inc. (CRNX) saw its stock price plummet by 5.58% during intraday trading on Friday, following the release of analyst reports on the company.

The significant decline appears to be driven by mixed or cautious analyst opinions on the healthcare stock. Analysts have recently been weighing in on Crinetics Pharmaceuticals, with their assessments likely influencing investor sentiment and triggering the sell-off.

While the specific details of the analyst ratings are contained within the research reports, the market reaction suggests the assessments introduced concerns or lowered expectations, leading to the sharp downward price movement in the session.